Cryosite Limited reported a robust half-year with revenue up 25% and net profit rising 36%, driven by strong demand in temperature-controlled logistics and a strategic warehouse acquisition that doubles its storage capacity.
- Revenue increased 25% to $8.27 million
- Net profit after tax rose 36% to $1.14 million
- Acquisition of Auburn warehouse doubles storage capacity
- Ultra-Frozen and Cryogenic segment revenue up 63%
- No interim dividend declared, focus on reinvestment
Strong Financial Performance
Cryosite Limited has delivered a standout half-year result for the period ending 31 December 2025, with revenue climbing 25% to $8.27 million and net profit after tax increasing 36% to $1.14 million. This growth reflects a strengthening of trading conditions and sustained demand across its specialised temperature-controlled logistics services.
The company’s earnings before interest, tax, depreciation and amortisation (EBITDA) surged 33% to $2.01 million, while earnings before interest and tax (EBIT) rose 43% to $1.58 million. Operational volumes increased by 30%, underscoring the expanding scale of Cryosite’s business.
Strategic Capacity Expansion
A key highlight of the half was Cryosite’s acquisition of a second warehouse facility at 100-104 Adderley Street West, Auburn, NSW. Completed in November 2025, this acquisition more than doubles the Group’s storage and warehousing footprint to over 4,200 square metres, providing critical capacity to meet accelerating demand.
The purchase was funded through a combination of $3.45 million in cash and a $6.65 million secured, interest-only loan facility from National Australia Bank. This strategic move enhances Cryosite’s operational flexibility and long-term control over infrastructure, positioning the company for scalable growth.
Growth in Ultra-Frozen and Cryogenic Services
The Ultra-Frozen and Cryogenic segment emerged as a major growth driver, with revenue up 63% to $1.22 million and EBITDA rising 44%. This segment supports advanced therapies such as cell and gene therapies, reflecting global trends in biopharmaceutical innovation. The number of active clinical trial sponsors increased by 39%, highlighting Cryosite’s strong reputation in this niche market.
Dividend Policy and Financial Position
In line with its growth strategy, Cryosite’s Board resolved not to declare an interim dividend for 1HFY26, opting instead to reinvest earnings into expansion initiatives. The Group ended the half with a solid cash balance of $2.54 million, despite capital outflows related to the warehouse acquisition.
The company maintains a strong balance sheet, supported by positive operating cash flows and a manageable debt facility. Discussions are underway to refinance the NAB loan facility maturing in October 2026, with management confident of securing favourable terms.
Commitment to ESG and Governance
Cryosite continues to prioritise environmental, social, and governance (ESG) initiatives, earning a Gold Medal rating from EcoVadis in 2025. Investments in energy-efficient infrastructure, workforce development, and safety programs underpin the company’s sustainable growth approach.
Governance enhancements during the period include strengthened supplier due diligence and internal controls, ensuring compliance as the Group scales its operations.
Bottom Line?
Cryosite’s strategic investments and robust financials set the stage for continued growth, but refinancing the NAB loan remains a key watchpoint.
Questions in the middle?
- Will Cryosite secure long-term refinancing for its NAB loan facility before maturity?
- How will the integration of the new Auburn warehouse impact operational efficiency and margins?
- What is the outlook for demand in the Ultra-Frozen and Cryogenic segment amid evolving biopharma trends?